BBT002

Phase 1Small molecule

BBT002 is one of 54 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Chronic Rhinosinusitis With Nasal PolypsActive, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 1

Active, not recruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

26 2

Flovent

GSK

Preclinical

6 3

Spiriva

Boehringer Ingelheim

Preclinical

15 4

Aclidinium Bromide

AstraZeneca

Preclinical

21 5

Duragesic

CCephalon

Preclinical

2 6

Coumadin

AAbbott

Preclinical

1 7

Narcan

SScienture

Preclinical

1 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

—9

Versed

CConrado Roberto Hoffmann Filho

Insulin Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Chronic Obstructive Pulmonary Disease

NCT07288554

Phase 1/2Not yet recruiting

Chronic Rhinosinusitis With Nasal Polyps

NCT07436949

Q3 2027

Phase 1Recruiting

Chronic Obstructive Pulmonary Disease

NCT06944925

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Recruiting·BBambusa Therapeutics·Phase 1·NCT07288554·68 enrolled

A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Patients With COPD or CRSwNP

Recruiting·BBambusa Therapeutics·Phase 1·NCT06944925·286 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma

Not yet recruiting·BBambusa Therapeutics·Phase 1/2·NCT07436949·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BBT002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BBT002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BBT002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bambusa Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBambusa Therapeutics

BBT002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Chronic Rhinosinusitis With Nasal Polyps1 trial

References

Drug Info

Quick Facts

Related News